[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 29 of about 29
1. Ma J, Wen ZS, Lin P, Wang X, Xie FY: The results and prognosis of different treatment modalities for solitary metastatic lung tumor from nasopharyngeal carcinoma: a retrospective study of 105 cases. Chin J Cancer; 2010 Sep;29(9):787-95
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The results and prognosis of different treatment modalities for solitary metastatic lung tumor from nasopharyngeal carcinoma: a retrospective study of 105 cases.
  • BACKGROUND AND OBJECTIVE: Nasopharyngeal carcinoma (NPC) is known for its propensity for distant metastases.
  • Solitary metastatic lung tumor from NPC is a distinctive group associated with a better survival.
  • This study was to find a more effective treatment modality and prognostic factors for the group.
  • The Cox univariate and multivariate analyses of gender, age, pathologic type, stage, adjuvant chemotherapy, evaluation of treatment for NPC, disease-free interval, size of metastatic tumor, pulmonary hilar and/or mediastinal lymph node metastasis, treatment modalities, recurrent distant metastases and/or relapse of NPC were conducted.
  • RESULTS: The local control rate was 53.8% in chemotherapy group, 88.0% in radiotherapy ± chemotherapy group, and 96.4% in operation ± chemotherapy group (P < 0.01).
  • The most promising progression-free survival (PFS) and overall survival (OS) were obtained with operation ± chemotherapy and followed by radiotherapy ± chemotherapy.
  • Both of them showed much better efficacy than chemotherapy (P < 0.001).
  • The T stage of NPC, size of metastatic tumor, hilar and/or mediastinal lymph node metastasis, and the treatment modality were independent prognostic factors.
  • CONCLUSIONS: Operation ± chemotherapy and radiotherapy ± chemotherapy are better treatment of solitary metastatic lung tumor from NPC, which could improve the local control and prolong the PFS and OS.
  • Chemotherapy is recommended for patients with higher T stage of NPC, size of metastatic tumor ≥ 3 cm, pulmonary hilar and/or mediastinal lymph node metastasis.
  • [MeSH-major] Carcinoma, Squamous Cell / secondary. Carcinoma, Squamous Cell / therapy. Lung Neoplasms / secondary. Lung Neoplasms / therapy. Nasopharyngeal Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Pneumonectomy / methods. Radiotherapy, High-Energy. Remission Induction. Retrospective Studies. Survival Rate. Young Adult

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20800020.001).
  • [ISSN] 1000-467X
  • [Journal-full-title] Chinese journal of cancer
  • [ISO-abbreviation] Chin J Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


2. Jiang G, Min H, Zhang J, Huang Y: [Value of regional intra-arterial induction chemotherapy for locally advanced nasopharyngeal carcinoma]. Zhonghua Er Bi Yan Hou Ke Za Zhi; 2001 Oct;36(5):376-9
Genetic Alliance. consumer health - Nasopharyngeal carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Value of regional intra-arterial induction chemotherapy for locally advanced nasopharyngeal carcinoma].
  • OBJECTIVE: To define the value of regional intra-arterial induction chemotherapy for locally advanced nasopharyngeal carcinoma (NPC).
  • METHODS: 121 locally advanced NPC(stage III-IV) patients confirmed by pathology were randomly divided into two groups before radiation, and the two groups were given two different methods of chemotherapy: regional intra-arterial chemotherapy (IACT) and systemic chemotherapy (SCT).
  • CONCLUSION: IACT is more reasonable than SCT as induction chemotherapy for these locally advanced NPC.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma, Squamous Cell / drug therapy. Nasopharyngeal Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Combined Modality Therapy. Female. Humans. Infusions, Intra-Arterial. Male. Middle Aged. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12761949.001).
  • [ISSN] 0412-3948
  • [Journal-full-title] Zhonghua er bi yan hou ke za zhi
  • [ISO-abbreviation] Zhonghua Er Bi Yan Hou Ke Za Zhi
  • [Language] chi
  • [Publication-type] Clinical Trial; English Abstract; Journal Article; Randomized Controlled Trial
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


3. Wu H, Lin Q, Yu ZH, Yang ZX, Feng LP: [Late course conformal radiotherapy combined with chemotherapy for stage III and IV a nasopharyngeal carcinoma]. Zhonghua Yi Xue Za Zhi; 2005 Jul 6;85(25):1778-80
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Late course conformal radiotherapy combined with chemotherapy for stage III and IV a nasopharyngeal carcinoma].
  • OBJECTIVE: To evaluate the effect and acute toxicity of late course conformal radiotherapy combined with chemotherapy for stage III and IV a nasopharyngeal carcinoma (NPC).
  • METHODS: Ninety-six patients with stage III and IV a NPC were randomly divided into 2 groups: test group (n = 46, undergoing late course conformal radiotherapy combined with chemotherapy) and control group (n = 50, undergoing conventional radiotherapy).
  • Both groups were treated with one-period chemotherapy, including cisplantin, 5-fluouracil, and calcium folinate, before and after the radiotherapy.
  • The radiotherapy of the test group consisted of 2 phases: 36.0 approximately 40.0 Gy in 18 approximately 20 fractions over 3.5-4 weeks as the first phase using conventional technique was delivered with 2 lateral opposing faciocervical fields, and then 30.0-46.0 Gy in 15-23 fractions over 3-4.5 weeks as the second phase using three-dimensional conformal radiotherapy (3D-CRT).
  • The nasopharyngeal 1 year control rate of the test group was 97.83%, significantly higher than that of the control group (78.00%, P = 0.03).
  • CONCLUSION: Late course conformal radiotherapy combined with chemotherapy effectively improves the disease control, delays the distant metastasis, and alleviates radioactivity damnification.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Nasopharyngeal Neoplasms / drug therapy. Nasopharyngeal Neoplasms / radiotherapy. Radiotherapy, Conformal
  • [MeSH-minor] Adolescent. Adult. Aged. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy. Cisplatin / administration & dosage. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Humans. Leucovorin / administration & dosage. Male. Middle Aged

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16253169.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Randomized Controlled Trial
  • [Publication-country] China
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


Advertisement
4. Chen K, Jiang Y, Wen H: [Clinical study on treatment of nasopharyngeal carcinoma by radio- and chemotherapy with supplementary moxibustion on Shenque point]. Zhongguo Zhong Xi Yi Jie He Za Zhi; 2000 Oct;20(10):733-5
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical study on treatment of nasopharyngeal carcinoma by radio- and chemotherapy with supplementary moxibustion on Shenque point].
  • OBJECTIVE: To evaluate the effect of supplementary moxibustion in treating III, IV a stage nasopharyngeal carcinoma (NPC) with radio- and chemotherapy.
  • They were treated with radiotherapy in routine or chemotherapy adopting AD protocol.
  • Salt-separated moxibustion on Shenque (Ren 8) point was given to the treated group from beginning of radio- and chemotherapy for 30 times as one therapeutic course.
  • RESULTS: The remission rate in the two groups after radio- and chemotherapy was not different significantly.
  • After radio- and chemotherapy, the blood content of malonyldialdehyde (MDA), middle molecular substance and sulfhydryl reduced the SOD activity ascended in the treated group, the difference was significant as compared with those in the control group (P < 0.05, P < 0.01).
  • CONCLUSION: The supplementary moxibustion on Shenque point could obviously reduce the toxic side-effect of advanced NPC patients treated with radio- and chemotherapy.

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11938806.001).
  • [ISSN] 1003-5370
  • [Journal-full-title] Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine
  • [ISO-abbreviation] Zhongguo Zhong Xi Yi Jie He Za Zhi
  • [Language] CHI
  • [Publication-type] Clinical Trial; English Abstract; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


5. Wang CT, Cao KJ, Li Y, Xie GF, Huang PY: [Prognosis analysis of nasopharyngeal carcinoma patients with distant metastasis]. Ai Zheng; 2007 Feb;26(2):212-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognosis analysis of nasopharyngeal carcinoma patients with distant metastasis].
  • BACKGROUND & OBJECTIVE: The incidence of distant metastasis is high in nasopharyngeal carcinoma (NPC).
  • Of the 128 patients, 112 were men and 16 were women, with a median age of 48 (range, 15-70); 54 received chemoradiotherapy, 48 received chemotherapy alone, 14 received radiotherapy alone, and 12 received no treatment.
  • The median survival time was 15.6 months (range, 0.8-96.6 months).
  • Univariate analysis showed that age (P=0.038), treatment modality (P=0.041), chemotherapy cycles (P=0.034), and short-term treatment response (P=0.007) were prognostic factors of NPC with distant metastasis.
  • Multivariate analysis showed that sex (P=0.013), chemotherapy cycles (P=0.032), N stage (P=0.011), and short-term treatment response (P<0.001) were independent prognostic factors.
  • CONCLUSION: Sex, chemotherapy cycles, and short-term treatment response are independent prognostic factors of NPC with distant metastasis.
  • [MeSH-major] Bone Neoplasms. Carcinoma, Squamous Cell. Lung Neoplasms. Nasopharyngeal Neoplasms
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / therapeutic use. Combined Modality Therapy. Female. Fluorouracil / therapeutic use. Follow-Up Studies. Humans. Liver Neoplasms / drug therapy. Liver Neoplasms / radiotherapy. Liver Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Particle Accelerators. Prognosis. Proportional Hazards Models. Radiotherapy, High-Energy. Remission Induction. Sex Factors. Survival Rate. Young Adult


6. Hu QY, Liu P, Wang L, Fu ZF: [Concurrent chemoradiotherapy followed by adjuvant chemotherapy for stage III-IVa nasopharyngeal carcinoma]. Ai Zheng; 2007 Apr;26(4):394-7
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Concurrent chemoradiotherapy followed by adjuvant chemotherapy for stage III-IVa nasopharyngeal carcinoma].
  • BACKGROUND & OBJECTIVE: Most studies on chemoradiotherapy for advanced nasopharyngeal carcinoma (NPC) showed that induction chemotherapy before radiotherapy could not improve the survival of the patients, but the effect of adjuvant chemotherapy after radiotherapy on advanced NPC is uncertain.
  • This study was to evaluate the efficacy of concurrent chemoradiotherapy followed by adjuvant chemotherapy on stage III-IVa nasopharyngeal carcinoma (NPC).
  • METHODS: A total of 80 patients with stage III-IVa NPC were randomized into test group (40 patients) and control group (40 patients).
  • Test group received concurrent chemotherapy of weekly cisplatin (25 mg/m2) for 6 weeks, and conventional radiotherapy of standard fractionation at 2 Gy/day to a total of 70 Gy to the nasopharynx, followed by adjuvant chemotherapy of cisplatin (25 mg/m2) and 5-fluorouracil (1000 mg/m2) daily for 3 days and repeated every 3 weeks for 3 cycles.
  • RESULTS: After treatment, 34 patients in test group and 32 in control group achieved complete remission (CR) (P>0.05); the CR rate of neck lymph node was significantly higher in test group than in control group (92.5% vs. 75.0%, P<0.05).
  • CONCLUSION: Concurrent chemoradiotherapy followed by adjuvant chemotherapy could improve the CR rate of neck lymph node, overall survival, and disease-free survival of stage III-IVa NPC patients, suppress distant metastasis, but increase the risk of grade III mucositis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / therapy. Nasopharyngeal Neoplasms / therapy. Radiotherapy, High-Energy
  • [MeSH-minor] Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Combined Modality Therapy. Disease-Free Survival. Dose Fractionation. Female. Fluorouracil / administration & dosage. Humans. Lymphatic Metastasis. Male. Middle Aged. Mucositis / chemically induced. Neoplasm Staging. Remission Induction. Survival Rate

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17430659.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Randomized Controlled Trial
  • [Publication-country] China
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


7. El-Weshi A, Khafaga Y, Allam A, Mosseri V, Ibrahim E, El-Serafi M, El-Badawi S: Neoadjuvant chemotherapy plus conventional radiotherapy or accelerated hyperfractionation in stage III and IV nasopharyngeal carcinoma--a phase II study. Acta Oncol; 2001;40(5):574-81
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant chemotherapy plus conventional radiotherapy or accelerated hyperfractionation in stage III and IV nasopharyngeal carcinoma--a phase II study.
  • A prospective phase II trial was initiated in previously untreated patients with locally advanced nasopharyngeal carcinoma (NPC).
  • The goal was to achieve improvement in locoregional control, disease-free interval and overall survival using induction chemotherapy and to compare conventional fractionation (CF) with an accelerated hyperfractionation (AHF) regimen.
  • Fifty patients were treated (5 AJCC Stage III, 45 Stage IV) with induction chemotherapy consisting of two cycles of cisplatin and 5-fluorouracil.
  • Patients were then randomized between CF and AHF therapy.
  • A clinical response to induction chemotherapy was reported in 86% of patients prior to radiotherapy (44% complete response, 42% partial response).
  • Patients with complete or major partial responses to induction chemotherapy had a significantly better 5-year overall survival (60%) and disease-free interval (59%) than those with no response or minor partial response (15% and 18% p = 0.009 and 0.0009).
  • Acute radiation reactions were more pronounced in the AHF group (p = 0.0002), and the incidence of late normal tissue injury was more frequent (p = 0.08).
  • With a median follow-up period of 55 months (range 4-120), the 5-year disease-free interval and overall survival rates were more favorable in the AHF group than in the CF group, but the differences were not significant (59% and 54% vs. 34% and 36%, respectively, HR for disease-free interval = 0.71; 95% CI, 0.27-1.88; p=0.198 and HR for overall survival = 0.81; 95% CI, 0.37-1.78; p=0.433).
  • The overall treatment failure rate was 48%.
  • Response to induction chemotherapy is strongly predictive for locoregional control, disease-free interval and overall survival.
  • The optimal chemotherapy dose and sequencing with radiotherapy needs to be investigated in future studies.
  • Distant metastases remain the main cause of treatment failure in NPC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma / drug therapy. Carcinoma, Squamous Cell / drug therapy. Chemotherapy, Adjuvant. Dose Fractionation. Nasopharyngeal Neoplasms / drug therapy. Radioisotope Teletherapy / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Cisplatin / adverse effects. Cisplatin / therapeutic use. Disease-Free Survival. Female. Fluorouracil / adverse effects. Fluorouracil / therapeutic use. Humans. Life Tables. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local. Prospective Studies. Radiation Injuries / etiology. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11669328.001).
  • [ISSN] 0284-186X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] Norway
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


8. Taussky D, Rufibach K, Huguenin P, Allal AS: Risk factors for developing a second upper aerodigestive cancer after radiotherapy with or without chemotherapy in patients with head-and-neck cancers: an exploratory outcomes analysis. Int J Radiat Oncol Biol Phys; 2005 Jul 1;62(3):684-9
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk factors for developing a second upper aerodigestive cancer after radiotherapy with or without chemotherapy in patients with head-and-neck cancers: an exploratory outcomes analysis.
  • PURPOSE: The objective was to assess the influence of treatment-related and patient-related factors on the risk of developing a second primary tumor (SPT) of the upper aerodigestive tract (UADT) in patients with locoregionally advanced nonmetastatic carcinomas of the head-and-neck region.
  • METHODS AND MATERIALS: The data of 521 patients with a minimum follow-up of 1 year were pooled: 224 patients from the Swiss Group for Clinical Cancer Research (SAKK) 10/94 trial, treated with 1.2 Gy b.i.d. to 74.4 Gy, and randomized to receive or not to receive simultaneous chemotherapy with cisplatin (excluding nasopharyngeal and maxillary sinus carcinomas); and 297 patients from Geneva, all treated with accelerated radiotherapy with concomitant boost to 69.9 Gy and predominantly cisplatin-based concomitant chemotherapy in 33% of patients (including 21 patients with nasopharyngeal carcinomas).
  • RESULTS: A total of 65 SPT of the UADT were observed after a median observation time of 4.7 years.
  • There were no SPTs after treatment for nasopharyngeal carcinoma.
  • In a multivariate logistic regression analysis, there was no difference in occurrence of SPT at 3 years with respect to the administration of chemotherapy (p = 0.31), age (p = 0.62), performance status (p = 0.61), gender (p = 0.27), presence of nodal disease (p = 0.51), or T stage (p = 0.72).
  • CONCLUSIONS: Our data do not suggest that addition of chemotherapy to radiotherapy influences the incidence of second cancers in patients with head-and-neck cancer.
  • [MeSH-major] Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / radiotherapy. Neoplasms, Second Primary / etiology
  • [MeSH-minor] Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Combined Modality Therapy. Databases as Topic. Female. Humans. Male. Middle Aged. Regression Analysis. Risk Factors

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15936546.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Cao KJ, Li Y, Xie GF, Hong MH: [Prognostic factors in nasopharyngeal carcinoma in childhood and adolescence]. Zhonghua Zhong Liu Za Zhi; 2006 Feb;28(2):134-7
Genetic Alliance. consumer health - Nasopharyngeal carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic factors in nasopharyngeal carcinoma in childhood and adolescence].
  • OBJECTIVE: To analyze the prognostic factors affecting long-term result in pediatric or adolescent nasopharyngeal carcinoma.
  • METHODS: From January 1984 to December 1998, 117 cases of pediatric and adolescent nasopharyngeal carcinoma proven by pathology were treated by radiotherapy and/or chemotherapy.
  • Of the 117 patients, 35 received chemotherapy before radiotherapy, 36 were treated with continuous radiotherapy and the other 81 with split-course radiotherapy.
  • A dose of 56 - 80 Gy/6 - 13 weeks (66.32 +/- 4.72 Gy) was given in the nasopharynx and 47 - 73 Gy/5 - 13 weeks (57.90 +/- 5.80 Gy) in the neck.
  • A monovariate analysis showed that the age (P = 0.0015), mode of biopsy (P = 0.0234), N stage (P = 0.0001), mode of irradiation (P = 0.0027), chemotherapy (P = 0.0056) and short-term result (P = 0.0000) were the significant prognostic factors.
  • The multivariate analysis demonstrated that the age (P = 0.027), N stage (P = 0.048), mode of irradiation (P = 0.009) and short-term result (P = 0.000) were the factors influencing prognosis of nasopharyngeal carcinoma in childhood and adolescence.
  • CONCLUSION: The mode of irradiation, N stage and short-term result are the significantly influencing factors of prognosis in pediatric and adolescent nasopharyngeal carcinoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell. Nasopharyngeal Neoplasms
  • [MeSH-minor] Adolescent. Child. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Neoplasm Recurrence, Local. Neoplasm Staging. Prognosis. Radiation Injuries / etiology. Radiotherapy, High-Energy / adverse effects. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16750020.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


10. Leung TW, Tung SY, Sze WK, Sze WM, Wong VY, O SK: Salvage brachytherapy for patients with locally persistent nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys; 2000 May 1;47(2):405-12
Hazardous Substances Data Bank. COBALT, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage brachytherapy for patients with locally persistent nasopharyngeal carcinoma.
  • PURPOSE: Locally persistent nasopharyngeal carcinoma (NPC) carries an increased risk of local failure if additional treatment is not given.
  • Fibreoptic nasopharyngoscopy was performed 3-6 weeks after completion of the primary external radiation therapy (ERT).
  • Eighty-seven patients were shown to have persistent viable disease at a median time of 6 weeks post-RT.
  • The distribution according to Ho's staging system at initial diagnosis was as follows: Stage I-8, II-33, III-41, IV-5; T1-19, T2-48, T3-20; N0-32, N1-22, N2-28, N3-5.
  • They were treated with HDR intracavitary brachytherapy, with either cobalt sources or an iridium source, giving 22.5-24 Gy in 3 weekly sessions in all but 4 patients.
  • Twelve patients were treated with neoadjuvant chemotherapy.
  • In assessing the local control, only the T staging was significant on multivariate analysis (p = 0.0004).
  • In the persistent group, the local failure rates of the patients treated with and without neoadjuvant chemotherapy were 17% (2/12) and 13% (10/75) respectively.
  • When early T-stage (T1 and T2) patients were grouped together for analysis, the iridium group again showed a statistically significant improvement in 5-year LFFS rate when it was compared with the cobalt group (95.3% vs. 76.5%, p = 0.03) and the ERT alone group (95.3% vs. 81.5%, p = 0.03).
  • The improvement of local control is attributed to a higher nasopharyngeal mucosal dose that is achieved by using small-size flexible applicators with an iridium source.
  • This information supports our speculation that an adequate booster treatment could compensate for inadequate primary treatment.
  • [MeSH-major] Brachytherapy / methods. Carcinoma / radiotherapy. Nasopharyngeal Neoplasms / radiotherapy
  • [MeSH-minor] Analysis of Variance. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy. Chemotherapy, Adjuvant. Cobalt / therapeutic use. Disease-Free Survival. Female. Humans. Iridium / therapeutic use. Male. Middle Aged. Neoplasm Staging. Proportional Hazards Models. Radiopharmaceuticals / therapeutic use. Retrospective Studies. Salvage Therapy

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • Hazardous Substances Data Bank. IRIDIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10802367.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 3G0H8C9362 / Cobalt; 44448S9773 / Iridium
  •  go-up   go-down


13. Xie GF, Cao KJ, Li Y, Huang PY: [Impact of dose boost in skull base on recurrence of stage T4 nasopharyngeal carcinoma]. Ai Zheng; 2005 Oct;24(10):1246-8
Genetic Alliance. consumer health - Nasopharyngeal carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Impact of dose boost in skull base on recurrence of stage T4 nasopharyngeal carcinoma].
  • BACKGROUND & OBJECTIVE: The recurrence rate in skull base is high for nasopharyngeal carcinoma (NPC) patients with cavernous sinus or/and sphenoid sinus involvement.
  • METHODS: A total of 120 stage T4 NPC patients with cavernous sinus or/and sphenoid sinus involvement proved by histopathology and computed tomography (CT) were treated in our hospital from Oct.
  • The irradiation dose was (71.55+/-3.09) Gy in nasopharynx and (58.95+/-6.16) Gy in neck.
  • Of the 120 patients, 27 received irradiation (6-10 Gy) in skull base after radiotherapy (boost group), 93 did not receive irradiation in skull base (control group).
  • Fifty-three patients, 41 in control group and 12 in boost group, received cisplatin-based chemotherapy for 1-3 cycles.
  • The median disease-freely survival time was longer in boost group than in control group (60 months vs. 30 months).
  • CONCLUSION: Dose boost in skull base can reduce the recurrence of stage T4 NPC in skull base and tends to enhance the disease-freely survival rate for NPC patients with cavernous sinus or/and sphenoid sinus involvementû it is recommended to such patients.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Nasopharyngeal Neoplasms / radiotherapy. Neoplasm Recurrence, Local / prevention & control. Paranasal Sinus Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16219141.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Cobalt Radioisotopes
  •  go-up   go-down


14. Chang JT, Lin CY, Chen TM, Kang CJ, Ng SH, Chen IH, Wang HM, Cheng AJ, Liao CT: Nasopharyngeal carcinoma with cranial nerve palsy: the importance of MRI for radiotherapy. Int J Radiat Oncol Biol Phys; 2005 Dec 1;63(5):1354-60
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nasopharyngeal carcinoma with cranial nerve palsy: the importance of MRI for radiotherapy.
  • PURPOSE: To evaluate various prognostic factors and the impact of imaging modalities on tumor control in patients with nasopharyngeal cancer (NPC) with cranial nerve (CN) palsy.
  • Imaging methods used varied over that period, and included conventional tomography (Tm) for 47 patients, computerized tomography (CT) for 195 patients, and magnetic resonance image (MRI) for 88 patients.
  • The median external RT dose was 70.2 Gy (range, 63-77.5 Gy).
  • A total of 139 patients received cisplatin-based chemotherapy, in 115 received as neoadjuvant or adjuvant chemotherapy and in 24 concomitant with RT.
  • Patients who had an MRI had a significantly better tumor control rate than those evaluated with CT or Tm, with a 15-30% improvement in local tumor control and survival.
  • Brachytherapy was associated with poorer local control, whereas a total external dose of more than 70 Gy improved local tumor control and marginally improved DSS.
  • Subgroup analysis in CT and MRI patients group, either DSS or OS was significantly associated with imaging modality, N stage, or location of or remission of CN palsy.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Cranial Nerve Diseases / radiotherapy. Magnetic Resonance Imaging. Nasopharyngeal Neoplasms / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging / methods. Prognosis. Recovery of Function. Retrospective Studies. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16297716.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Xie FY, Qi SN, Hu WH, Zou GR, Peng M, Li JS: [Comparison of efficacy of docetaxel combined cisplatin (TP regimen) and cisplatin combined 5-fluorouracil (PF regimen) on locally advanced nasopharyngeal carcinoma]. Ai Zheng; 2007 Aug;26(8):880-4
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Comparison of efficacy of docetaxel combined cisplatin (TP regimen) and cisplatin combined 5-fluorouracil (PF regimen) on locally advanced nasopharyngeal carcinoma].
  • BACKGROUND & OBJECTIVE: Docetaxel and cisplatin (DDP) are effective drugs for head and neck tumors.
  • Stage II-III clinical trial of TP regimen (docetaxel combined DDP) for head and neck tumors has completed.
  • This study was to compare the efficacy and toxicity of TP regimen and PF regimen [DDP combined 5-fluorouracil (5-FU)] in treating nasopharyngeal carcinoma (NPC), to provide a new chemotherapeutic regimen for NPC.
  • RESULTS: The mean number of chemotherapy cycles was significantly higher in TP group than in PF group (3.85 cycles vs. 2.75 cycles, P<0.001).
  • After induction chemotherapy, in TP group, 18 achieved partial remission (PR) and 2 had stable disease (SD) for nasopharyngeal lesions, 7 achieved complete remission (CR), 11 achieved PR and 2 had SD for regional lymph nodes; in PF group, 17 achieved PR and 3 had SD for nasopharyngeal lesions, 2 achieved CR, 15 achieved PR and 1 had SD for regional lymph nodes.
  • After concurrent chemoradiotherapy, all in TP group and 18 in PF group achieved CR for nasopharyngeal lesions, and 19 in TP group and 15 in PF group achieved CR for regional lymph nodes.
  • The occurrence rates of grade 3-4 neutropenia were significantly higher in TP group than in PF group (40.5% vs. 0% after induction chemotherapy, 40.5% vs. 10.2% after concurrent radiochemotherapy, P<0.05).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Nasopharyngeal Neoplasms / drug therapy
  • [MeSH-minor] Adult. Anemia / chemically induced. Cisplatin / administration & dosage. Cisplatin / adverse effects. Cisplatin / therapeutic use. Combined Modality Therapy. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Fluorouracil / therapeutic use. Humans. Leukopenia / chemically induced. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Particle Accelerators. Radiotherapy, High-Energy / adverse effects. Stomatitis / etiology. Taxoids / administration & dosage. Taxoids / adverse effects

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17697552.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Randomized Controlled Trial
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; CF regimen
  •  go-up   go-down


16. Li P, Ai P, Chen L, Yang Y, Li Z, Zhang H, Xu Y, Hong Y, Hao D: [Analysis on clinical data of 677 death cases with nasopharyngeal carcinoma]. Lin Chuang Er Bi Yan Hou Ke Za Zhi; 2002 Jan;16(1):15-6
Genetic Alliance. consumer health - Nasopharyngeal carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis on clinical data of 677 death cases with nasopharyngeal carcinoma].
  • OBJECTIVE: To study the death causes in 677 patients with nasopharyngeal carcinoma (NPC).
  • The main age stage was from forty to sixty.
  • The pathological type was mostly poorly differentiated squamous cell carcinoma.
  • The cases with stage III-IV disease were account for 81.3%.
  • The patients treated by radiotherapy combined with chemotherapy survived longer than those treated by radiotherapy alone (P < 0.05).
  • The majority of the patients died of distal metastasis (372, 54.9%) and local-regional lymph node uncontrolled (142, 20.9%) after treatment.
  • CONCLUSION: The main death causes of the patients with NPC in our investigation were distal metastasis and local-regional recurrence.
  • The treatment of radiotherapy plus chemotherapy probably increases survival time and reduces the death rate in patients with NPC.
  • [MeSH-major] Carcinoma, Squamous Cell / mortality. Nasopharyngeal Neoplasms / mortality
  • [MeSH-minor] Adolescent. Adult. Aged. Cause of Death. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local / mortality

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11944472.001).
  • [Journal-full-title] Lin chuang er bi yan hou ke za zhi = Journal of clinical otorhinolaryngology
  • [ISO-abbreviation] Lin Chuang Er Bi Yan Hou Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


17. Elser C, Siu LL, Winquist E, Agulnik M, Pond GR, Chin SF, Francis P, Cheiken R, Elting J, McNabola A, Wilkie D, Petrenciuc O, Chen EX: Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. J Clin Oncol; 2007 Aug 20;25(24):3766-73
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma.
  • PURPOSE: To determine the efficacy and safety of single-agent sorafenib in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) and nasopharyngeal carcinoma (NPC).
  • Patients had <or= one line of chemotherapy for recurrent and/or metastatic disease, Eastern Cooperative Oncology Group performance status of <or= 2, and adequate organ function.
  • At the end of stage 1, efficacy criteria for further accrual were not met, but the study was amended to enroll an additional five patients for paired tumor biopsies.
  • The median time to progression was 1.8 months (95% CI, 1.6 to 3.4 months), and median overall survival time was 4.2 months (95% CI, 3.6 to 8.7 months).
  • Biomarker analysis of paired tumor samples before and after treatment with sorafenib revealed a decrease of pERK in all five patients, with a decrease in Ki67 in four patients, consistent with a disruption of ERK signaling.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Benzenesulfonates / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Head and Neck Neoplasms / drug therapy. Nasopharyngeal Neoplasms / drug therapy. Pyridines / therapeutic use
  • [MeSH-minor] Adult. Aged. Disease Progression. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Niacinamide / analogs & derivatives. Phenylurea Compounds. Protein Kinase Inhibitors / therapeutic use. Survival Rate. raf Kinases / antagonists & inhibitors


18. Cao KJ, Li Y, Huang PY, Xie GF, Huang TB, Hong MH: [Long-term efficacy of radiotherapy on children with nasopharyngeal carcinoma]. Ai Zheng; 2004 Nov;23(11):1322-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Long-term efficacy of radiotherapy on children with nasopharyngeal carcinoma].
  • BACKGROUND & OBJECTIVE: Nasopharyngeal carcinoma (NPC) in children is a particular type of NPC with poor prognosis.
  • This study was to analyze long-term treatment efficacy, and relevant factors influencing prognosis of NPC in children.
  • Radiation doses were 52-74 Gy/6-13 weeks [(64.68+/-5.68) Gy] in nasopharynx, and 46-73 Gy/5-13 weeks [(57.77+/-5.86) Gy] in neck; 21 received 1-3 cycles of chemotherapy (cisplatin, bleomycin, 5-fluoroucil, vincristine, and cyclophosphamide) before radiotherapy.
  • Clinical stage (P=0.046), mode of biopsy (P=0.024), radiation dose in nasopharynx (P=0.049), and short-term efficacy (P=0.005) correlated with prognosis of these patients.
  • CONCLUSIONS: Clinical stage, mode of biopsy, radiation dose in nasopharynx, short-term efficacy may influence prognosis of NPC in children.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Nasopharyngeal Neoplasms / radiotherapy. Radiotherapy, High-Energy
  • [MeSH-minor] Adolescent. Body Height / radiation effects. Child. Cobalt Radioisotopes / adverse effects. Cobalt Radioisotopes / therapeutic use. Female. Follow-Up Studies. Humans. Male. Menstruation Disturbances / etiology. Neoplasm Staging. Particle Accelerators. Prognosis. Radiotherapy Dosage. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15522182.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Cobalt Radioisotopes
  •  go-up   go-down


19. Oksüz DC, Meral G, Uzel O, Cağatay P, Turkan S: Reirradiation for locally recurrent nasopharyngeal carcinoma: treatment results and prognostic factors. Int J Radiat Oncol Biol Phys; 2004 Oct 1;60(2):388-94
Genetic Alliance. consumer health - Nasopharyngeal carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reirradiation for locally recurrent nasopharyngeal carcinoma: treatment results and prognostic factors.
  • PURPOSE: To analyze the results and evaluate the prognostic factors in the retreatment of locally recurrent nasopharyngeal carcinoma.
  • METHODS AND MATERIALS: Forty-one patients with locally recurrent nasopharyngeal carcinoma, who were reirradiated between 1979 and 2000, were retrospectively analyzed.
  • According to the 1998 TNM staging system of the American Joint Committee on Cancer, the recurrent disease was Stage I in 5 (12.2%), Stage II in 11 (26.8%), Stage III in 6 (14.6%), and Stage IV in 19 (46.4%) patients.
  • Treatment was delivered with 4-6 MV X-rays or Co-60 gamma rays.
  • The median reirradiation dose was 50 Gy.
  • Treatment was delivered at 1.8-2 Gy/fraction daily, 5 days a week.
  • Chemotherapy was used in 41.5% of the patients.
  • For overall survival age, total reirradiation dose, stage, T stage were significant.
  • On multivariate analysis only total dose (p = 0.005) remained significant for local progression-free rate and total reirradiation dose (p = 0.02), interval to recurrence (p = 0.03), stage (p = 0.018) were significant for overall survival.
  • CONCLUSIONS: Early diagnosis of local recurrence and high-dose reirradiation (60 Gy) are crucial for improving the local control and survival.
  • [MeSH-major] Carcinoma / radiotherapy. Nasopharyngeal Neoplasms / radiotherapy. Neoplasm Recurrence, Local / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Analysis of Variance. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Proportional Hazards Models. Radiation Injuries / etiology. Radiotherapy Dosage. Remission Induction. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15380570.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Chen CL, Sheen TS, Lou IU, Huang AC: Expression of multidrug resistance 1 and glutathione-S-transferase-Pi protein in nasopharyngeal carcinoma. Hum Pathol; 2001 Nov;32(11):1240-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of multidrug resistance 1 and glutathione-S-transferase-Pi protein in nasopharyngeal carcinoma.
  • Radiotherapy is the modality of choice for the treatment of nasopharyngeal carcinoma (NPC).
  • However, systemic chemotherapy has recently been found to play an increasing role in the treatment of advanced or metastatic disease.
  • The status of drug resistance gene expression that has crucial impact on chemotherapy has not been fully addressed for patients with NPC.
  • The results were correlated with the expression of Epstein-Barr virus (EBV) latent protein, latent membrane protein 1 (LMP1), and clinicopathologic features, including stage, histopathologic types, and survival rates.
  • We concluded that the expression of GST-Pi was more frequent in NPC tumor tissues than the expression of MDR-1.
  • The expression of MDR-1 correlated with clinicopathologic features of primary NPC, including the histopathologic types and survival rates, but not with disease stage.
  • [MeSH-major] Carcinoma / metabolism. Glutathione Transferase / metabolism. Isoenzymes / metabolism. Nasopharyngeal Neoplasms / metabolism. P-Glycoprotein / metabolism
  • [MeSH-minor] Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Drug Resistance, Neoplasm. Glutathione S-Transferase pi. Humans. Immunohistochemistry. Neoplasm Metastasis. Neoplasm Recurrence, Local / metabolism. Neoplasm Recurrence, Local / pathology. Prognosis. Survival Analysis. Viral Matrix Proteins / immunology. Viral Matrix Proteins / metabolism

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 by W.B. Saunders Company
  • (PMID = 11727264.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / EBV-associated membrane antigen, Epstein-Barr virus; 0 / Isoenzymes; 0 / P-Glycoprotein; 0 / Viral Matrix Proteins; EC 2.5.1.18 / GSTP1 protein, human; EC 2.5.1.18 / Glutathione S-Transferase pi; EC 2.5.1.18 / Glutathione Transferase
  •  go-up   go-down


21. Dong XR, Zhang T, Fan L, Zhang S, Wu G: Parotid gland metastasis of nasopharyngeal carcinoma: case report and review of the literature. J Int Med Res; 2009 Nov-Dec;37(6):1994-9
Genetic Alliance. consumer health - Nasopharyngeal carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Parotid gland metastasis of nasopharyngeal carcinoma: case report and review of the literature.
  • Parotid metastasis of nasopharyngeal carcinoma (NPC) is extremely rare.
  • The current case report presents the history of a 41-year old male with the primary symptom of a right parotid gland mass who was diagnosed with NPC by histopathology in 2006 and was staged as having cT(3)N(2)M(0) disease (stage III, American Joint Committee on Cancer staging system, 2002).
  • Histopathological examination of a partial excision of the mass on the right parotid and the neoplasm in the pharynx nasalis revealed poorly differentiated squamous cell carcinoma.
  • The patient received radiotherapy and concurrent chemotherapy.
  • Grade 2 skin reaction, grade 2 oropharyngeal mucositis and grade 3 xerostomia were detected during treatment.
  • The patient achieved a complete clinical response by 1 month after treatment.
  • At the last follow-up in August 2009, the patient was in a good condition and living a normal life.
  • [MeSH-major] Nasopharyngeal Neoplasms / pathology. Parotid Neoplasms / secondary
  • [MeSH-minor] Adult. Dose-Response Relationship, Radiation. Humans. Male. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20146900.001).
  • [ISSN] 0300-0605
  • [Journal-full-title] The Journal of international medical research
  • [ISO-abbreviation] J. Int. Med. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 20
  •  go-up   go-down


22. Lee CC, Ho HC, Su YC, Lee MS, Hsiao SH, Hwang JH, Hung SK, Chou P, Lee CC: Bidimensional measurement of nasopharyngeal carcinoma: a simple method to predict outcomes. Clin Otolaryngol; 2009 Feb;34(1):26-33
Genetic Alliance. consumer health - Nasopharyngeal carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bidimensional measurement of nasopharyngeal carcinoma: a simple method to predict outcomes.
  • OBJECTIVES: To determine whether the standard techniques of measuring tumour size could be applied to the measurement of nasopharyngeal carcinoma.
  • PARTICIPANTS: All patients with nasopharyngeal carcinoma were included.
  • MAIN OUTCOME MEASURES: Ninety-eight patients with newly diagnosed nasopharyngeal carcinoma were treated with high-dose radiotherapy and chemotherapy were enrolled in this study.
  • Computed tomography-derived primary tumour volume, bidimensional measurement and unidimensional measurement were recorded.
  • Using age, gender, chemotherapy status and T-stage as covariate, bidimensional measurement remained an independent prognostic factor for any relapse [Hazard ratio = (HR) 1.066; P = 0.029], and overall survival (HR = 1.097; P = 0.007).
  • CONCLUSIONS: When using simple measurement to evaluate nasopharyngeal carcinoma, the bidimensional measurement may be used to measure size at diagnosis.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Nasopharyngeal Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Predictive Value of Tests. Prognosis. Prospective Studies. ROC Curve. Radiotherapy, High-Energy. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19260882.001).
  • [ISSN] 1749-4486
  • [Journal-full-title] Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery
  • [ISO-abbreviation] Clin Otolaryngol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


23. Han F, Wang HY, Xia YF, Liu MZ, Zhao C, Lu TX: [Correlation of DNA ploidy in fresh tumor tissues to prognosis of nasopharyngeal carcinoma]. Ai Zheng; 2007 Sep;26(9):1015-9
Genetic Alliance. consumer health - Nasopharyngeal carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Correlation of DNA ploidy in fresh tumor tissues to prognosis of nasopharyngeal carcinoma].
  • BACKGROUND & OBJECTIVE: Because of the heterogeneity of nasopharyngeal carcinoma (NPC), current TNM staging system could not indicate the prognosis of individual patients.
  • 2000, the DNA ploidy in fresh NPC samples from 53 naive NPC patients with poorly differentiated squamous cell carcinoma was analyzed by flow cytometry (FCM).
  • Of the 53 patients, 32 received radiotherapy alone, 21 received 1 course of chemotherapy (cisplatin plus 5-fluorouracil) at the end of the 4th week of radiotherapy.
  • The differences in age, sex, clinical stage, N stage, and chemotherapy were not significant between diploid group and heteroploid group (P>0.05).
  • By Cox regression analysis, DNA ploidy and clinical stage were correlative factors for overall survival rate (P=0.020, P=0.017) and distant metastasis-free survival rate (P=0.007, P=0.011).
  • CONCLUSIONS: DNA ploidy and clinical stage are independent prognostic factors of NPC.
  • [MeSH-major] Aneuploidy. Carcinoma, Squamous Cell / genetics. DNA, Neoplasm / genetics. Diploidy. Nasopharyngeal Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / secondary. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Radiotherapy, High-Energy. Survival Rate. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17927864.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


24. Xie FY, Huang HY, Hu JZ: [Observation on effect of radiotherapy and antike capsule combination therapy in treating nasopharyngeal cancer patients]. Zhongguo Zhong Xi Yi Jie He Za Zhi; 2001 Dec;21(12):888-90
MedlinePlus Health Information. consumer health - Herbal Medicine.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Observation on effect of radiotherapy and antike capsule combination therapy in treating nasopharyngeal cancer patients].
  • OBJECTIVE: To compare the effect of radiotherapy (RT) combined with Antike capsule (AC) and RT alone in treating nasopharyngeal cancer (NPC) patients.
  • METHODS: Eighty-nine patients with pathologically confirmed NPC (stage II-IV) were randomly divided into two groups: group A (46 cases) were treated with RT, receiving 65-70 Gy/6.5-7 weeks to nasopharynx region and the same dosage to neck region, and AC was given in combination.
  • The total dosis of RT for complete remission (CR) of primary nasopharyngeal tumor and neck lymph nodes, the CR rate and the changes of peripheral NK cell, T lymphocyte subsets in the two groups were compared.
  • RESULTS: The total dosis of RT for CR in group A and B were 41.6 +/- 8.9 Gy vs 50.7 +/- 9.2 Gy for primary nasopharyngeal tumor, P < 0.05 and 47.4 +/- 10.3 Gy vs 56.2 +/- 9.7 Gy for neck lymph nodes, P < 0.05.
  • The CR rate of primary nasopharyngeal tumor in group A and B were 93.5% and 88.4% respectively, P < 0.05.
  • The activity of NK cell as well as T3, T4 in peripheral blood increased significantly in the group A after treatment, P < 0.05, while in group B, T3, T4 lowered significantly, P < 0.05.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12575586.001).
  • [ISSN] 1003-5370
  • [Journal-full-title] Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine
  • [ISO-abbreviation] Zhongguo Zhong Xi Yi Jie He Za Zhi
  • [Language] CHI
  • [Publication-type] Clinical Trial; English Abstract; Journal Article; Randomized Controlled Trial
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Capsules; 0 / Cobalt Radioisotopes; 0 / Drugs, Chinese Herbal
  •  go-up   go-down


25. Fang FM, Li CF, Chien CY, Rau KM, Huang HY: Immunohistochemical expression of epidermal growth factor receptor and cyclooxygenase-2 in pediatric nasopharyngeal carcinomas: no significant correlations with clinicopathological variables and treatment outcomes. Int J Pediatr Otorhinolaryngol; 2007 Mar;71(3):447-55
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical expression of epidermal growth factor receptor and cyclooxygenase-2 in pediatric nasopharyngeal carcinomas: no significant correlations with clinicopathological variables and treatment outcomes.
  • Epidermal growth factor receptor (EGFR) and cyclooxygenase-2 (COX-2) were separately found associated with prognosis in adult patients with nasopharyngeal carcinoma (NPC).
  • Thirty consecutive NPC patients aged<or==20 years and treated by radiotherapy (RT) with (n=14) or without (n=16) systemic chemotherapy (CT) were accrued between 1988 and 2001 in a single institute.
  • The expression levels of these two oncoproteins did not significantly correlate with each other, DFS, OS, and any of clinicopathological factors, including histological subtype, AJCC stage, T stage, and N stage.
  • The only significant prognosticator predictive of adverse outcomes was AJCC stage IV at presentation, which, compared with lower-staged diseases, decreased the rates from 85.2% to 55.6% at 5 years for both DFS (p=0.05) and OS (p=0.05).
  • Such high frequencies provide the basis of combined targeted therapy by specific pharmacological inhibitors to enhance the effects of RT and CT.
  • [MeSH-major] Carcinoma, Squamous Cell. Cyclooxygenase 2 / immunology. Nasopharyngeal Neoplasms. Receptor, Epidermal Growth Factor / immunology
  • [MeSH-minor] Adolescent. Adult. Disease-Free Survival. Female. Humans. Immunohistochemistry. Male. Neoplasm Staging. Prognosis. Treatment Outcome

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17208308.001).
  • [ISSN] 0165-5876
  • [Journal-full-title] International journal of pediatric otorhinolaryngology
  • [ISO-abbreviation] Int. J. Pediatr. Otorhinolaryngol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] EC 1.14.99.1 / Cyclooxygenase 2; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


26. Yip YL, Tsao SW: Regulation of p63 expression in primary and immortalized nasopharyngeal epithelial cells. Int J Oncol; 2008 Oct;33(4):713-24
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regulation of p63 expression in primary and immortalized nasopharyngeal epithelial cells.
  • Interestingly, p53 mutation is uncommon in nasopharyngeal carcinoma (NPC).
  • The DeltaNp63 has been postulated to have a dominant-negative effect on the function of the p53 gene and may play a role in the pathogenesis of nasopharyngeal carcinoma.
  • In this study, we defined the expression profile of p63 and its various isoforms in primary and immortalized nasopharyngeal epithelial cells.
  • Elevated expression of p63 was generally detected in both primary and immortalized nasopharyngeal epithelial cells at their proliferation stage and the predominant isoform of p63 expressed was DeltaNp63alpha. p63 expression was suppressed upon cellular senescence of primary nasopharyngeal epithelial cells and induction of terminal differentiation in immortalized nasopharyngeal epithelial cells.
  • Expression of DeltaNp63 alone was able to drive clonal proliferation in primary nasopharyngeal cells in culture while downregulation of DeltaNp63 induced cellular apoptosis.
  • All these results support a role of DeltaNp63 in proliferation and immortalization which facilitates pathogenesis of nasopharyngeal carcinoma.
  • TGFbeta and retinoic acid downregulated the expression of p63 in immortalized nasopharyngeal epithelial cells and may play a role in regulating differentiation in squamous epithelial cells with potential applications in prevention and treatment of nasopharyngeal carcinoma.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Epithelial Cells / drug effects. Epithelial Cells / metabolism. Gene Expression Regulation, Neoplastic. Mutation. Nasopharyngeal Neoplasms / drug therapy. Trans-Activators / metabolism. Transforming Growth Factor beta1 / metabolism. Tumor Suppressor Proteins / metabolism
  • [MeSH-minor] Cell Aging. Cell Line. Cell Proliferation. DNA, Complementary / metabolism. Humans. Models, Biological. RNA / metabolism. Retroviridae / genetics. Transcription Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18813784.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / DNA, Complementary; 0 / TGFB1 protein, human; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Transforming Growth Factor beta1; 0 / Tumor Suppressor Proteins; 63231-63-0 / RNA
  •  go-up   go-down


27. Altun M, Demiral AN, Meral R, Kaytan E, Cosar R, Disci R, Dizdar Y: Prognostic significance of hemoglobin concentration in nasopharyngeal carcinoma: does treatment-induced anemia have negative effect? In Vivo; 2003 Sep-Oct;17(5):483-7
Hazardous Substances Data Bank. PLATINUM COMPOUNDS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of hemoglobin concentration in nasopharyngeal carcinoma: does treatment-induced anemia have negative effect?
  • PURPOSE: To assess the value of hemoglobin concentration (HC) in predicting treatment outcomes in nasopharyngeal carcinoma (NPC) patients treated with chemotherapy (CT) and radiotherapy (RT).
  • Along with other known risk factors (sex, age, histopathology, T stage, N stage, bilateral neck involvement, cranial nerve involvement and total RT time), the prognostic value of SA and MDHC were evaluated by Cox-regression.
  • CONCLUSION: MDHC and SA adversely affect treatment outcome in NPC patients treated with CT and RT.
  • [MeSH-major] Anemia. Carcinoma, Squamous Cell / pathology. Hemoglobins / analysis. Nasopharyngeal Neoplasms / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy / methods. Disease-Free Survival. Female. Humans. Male. Platinum Compounds / administration & dosage. Treatment Outcome

  • Genetic Alliance. consumer health - Anemia.
  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • MedlinePlus Health Information. consumer health - Anemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14598613.001).
  • [ISSN] 0258-851X
  • [Journal-full-title] In vivo (Athens, Greece)
  • [ISO-abbreviation] In Vivo
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Hemoglobins; 0 / Platinum Compounds
  •  go-up   go-down


28. Chee G, Mok P, Sim R: Squamous cell carcinoma of the temporal bone: diagnosis, treatment and prognosis. Singapore Med J; 2000 Sep;41(9):441-6, 451
Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous cell carcinoma of the temporal bone: diagnosis, treatment and prognosis.
  • Squamous cell carcinoma of the external ear canal is an uncommon condition that is associated with a poor outcome.
  • The development of an accepted staging system has not been forthcoming and this has inhibited the formation of an evidence-based therapeutic protocol.
  • We report the findings in 14 patients with squamous cell carcinoma of the external ear canal treated in our institutions.
  • Four patients had a history of chronic ear discharge and one had previous radiotherapy for nasopharyngeal carcinoma.
  • With combination treatment involving surgery, radiotherapy and chemotherapy, disease free survival achieved was 69% (9 of 13) over a mean follow-up period of 24.7 months.
  • One patient absconded treatment.
  • Patients with early stage tumours faired better than patients with advanced tumours (100% vs 33%).
  • [MeSH-major] Carcinoma, Squamous Cell. Skull Neoplasms. Temporal Bone / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11193117.001).
  • [ISSN] 0037-5675
  • [Journal-full-title] Singapore medical journal
  • [ISO-abbreviation] Singapore Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


29. Wolden SL, Steinherz PG, Kraus DH, Zelefsky MJ, Pfister DG, Wollner N: Improved long-term survival with combined modality therapy for pediatric nasopharynx cancer. Int J Radiat Oncol Biol Phys; 2000 Mar 1;46(4):859-64
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improved long-term survival with combined modality therapy for pediatric nasopharynx cancer.
  • PURPOSE: Nasopharynx cancer is a rare malignancy in childhood.
  • This study aims to determine the role of chemotherapy, the optimal dose of radiation, and the long-term outcome for children with locoregional disease.
  • METHODS AND MATERIALS: Thirty-three patients [median age 14 (range: 12-20) years] were treated for Stage I-IVB nasopharynx cancer.
  • Thirteen patients (39%) received radiotherapy alone and 20 patients (61%) had chemotherapy and radiotherapy.
  • The median radiation dose to the primary tumor was 66 Gy (range: 54-72 Gy).
  • The median follow-up time for surviving patients was 8.4 years (range: 0.5-23.6 years).
  • Locoregional control was improved for patients treated with radiation doses > 60 Gy compared to those receiving < or = 60 Gy (93% vs. 60%, p < 0.03).
  • The addition of chemotherapy had no significant effect on locoregional control but did reduce the development of distant metastases (16% vs. 57%, p = 0.01).
  • Combined modality therapy improved 10-year disease-free survival (84% vs. 35%, p < 0.01) and survival (78% vs. 33%, p < 0.05) over radiation alone.
  • The 10-year actuarial rate of severe complications was 24%.60 Gy are used for gross disease.
  • The addition of chemotherapy decreases the risk of distant metastases and increases survival.
  • [MeSH-major] Carcinoma / drug therapy. Carcinoma / radiotherapy. Nasopharyngeal Neoplasms / drug therapy. Nasopharyngeal Neoplasms / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents / adverse effects. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / radiotherapy. Child. Cisplatin / adverse effects. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Neoplasms, Second Primary / etiology. Radiotherapy / adverse effects. Radiotherapy Dosage. Retrospective Studies. Survival Rate

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10705006.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down






Advertisement